Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04284280 · ClinicalTrials.gov registry record · NA
Early Routine vs. Selective Human Milk Fortification in Extremely Preterm Infants
A NA study of Necrotizing Enterocolitis and Poor Growth in Extremely Preterm Infants, sponsored by Crouse Hospital.
- Recruiting
- Registry status
- NA
- Development phase
- 200
- Enrollment target
- 1
- Study location
NCT04284280: Recruiting NA study of Necrotizing Enterocolitis and Poor Growth in Extremely Preterm Infants, sponsored by Crouse Hospital.
NCT04284280 is a NA study of Necrotizing Enterocolitis and Poor Growth in Extremely Preterm Infants that is actively recruiting participants, run by Crouse Hospital. The registered enrollment target is 200 participants, below the 299-participant average among 14 other Necrotizing Enterocolitis trials with a reported enrollment target (33% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04284280, a NA study of Necrotizing Enterocolitis and Poor Growth in Extremely Preterm Infants, is actively recruiting participants, sponsored by Crouse Hospital.
- RECRUITING
- Registry status
- NA
- Development phase
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
The aim of the project is to study the effects of fortification (using a Human Milk Donor Fortifier) of an exclusive preterm human milk diet on outcome of extremely preterm neonates, born at less or equal to 27 weeks.
Primary Outcome
Compare the in-hospital growth in extremely preterm infants between routine fortification vs selective fortifications groups
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Routine vs Selective use of Human Milk Donor Fortifier
Study Locations (1)
New York
- Crouse Hospital - Syracuse
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2020-02-15 |
| Est. Completion | 2027-02-01 |
| Phase | NA |
What NCT04284280 shows while recruiting
NCT04284280 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 299-participant average among 14 other Necrotizing Enterocolitis trials with a reported enrollment target (33% lower).
The record links to 2 conditions, with Necrotizing Enterocolitis appearing as the primary indexed condition, and to 1 intervention - of which Routine vs Selective use of Human Milk Donor Fortifier is the first listed.
NCT04284280 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT04284280 about?
NCT04284280 is a clinical study titled "Early Routine vs. Selective Human Milk Fortification in Extremely Preterm Infants". The aim of the project is to study the effects of fortification (using a Human Milk Donor Fortifier) of an exclusive preterm human milk diet on outcome of extremely preterm neonates, born at less or equal to 27 weeks.
What is the current status of trial NCT04284280?
This trial is currently recruiting. It is a NA study. The enrollment target is 200 participants. The study started on 2020-02-15. Estimated completion is 2027-02-01.
What conditions does trial NCT04284280 study?
This clinical trial studies the following conditions: Necrotizing Enterocolitis, Poor Growth in Extremely Preterm Infants.
What interventions are being tested in trial NCT04284280?
The interventions under investigation include: Routine vs Selective use of Human Milk Donor Fortifier (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT04284280?
This trial is sponsored by Crouse Hospital, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04284280 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Necrotizing Enterocolitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04284280's enrollment target sits among peer trials
200 6th of 14 higher than 8 of 14 other Necrotizing Enterocolitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Necrotizing Enterocolitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Collaborative Research Group for Necrotizing Enterocolitis
COMPLETED · NA
-
Comparison of Two Surgical Treatments for Necrotizing Enterocolitis in Human Infants
COMPLETED · NA
-
Early Predictors of Necrotizing Enterocolitis in Neonates
RECRUITING
-
Study to Assess the Safety, Tolerability, and Preliminary Efficacy of ST266 in Infants With Necrotizing Enterocolitis
RECRUITING · Phase 1
-
A Cohort Study of the Intestinal Microbiota of Premature Infants
ACTIVE NOT RECRUITING
-
IBP-9414 for the Prevention of Necrotizing Enterocolitis - The Connection Study
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI